Tesamorelin/Ipamorelin (13:3 ratio, 13 mg tesamorelin + 3 mg Ipamorelin, 16 mg total) is a GHRH-focused dual-secretagogue blend emphasizing growth hormone-releasing hormone receptor pathway dominance. This formulation supports preclinical research prioritizing GHRH signaling with minimal GHS-R pathway contribution, enabling investigation of GHRH-dependent GH secretion mechanisms with subsidiary GHS-R modulation.

Chemical Specifications:

• Chemical Name: Tesamorelin (GHRH analog) + Ipamorelin (GHS-R agonist)
• Molecular Formula: Combined C166H265N47O45S + C38H50N8O5 (approximate)
• Molecular Weight: Combined ~3793 g/mol (approximate)
• Compound Class: GHRH-focused dual secretagogue blend (13:3 ratio)

The 13:3 tesamorelin:Ipamorelin ratio heavily favors GHRH pathway activation while incorporating minimal GHS-R1a signaling. This composition models research examining primary GHRH-dependent GH secretion with slight accessory GHS-R pathway contribution.

Research Applications:

• Investigating GHRH-dependent GH secretion with minimal GHS-R contribution
• Characterizing GHRH pathway dynamics in mixed-agonist protocols
• Modeling GH axis function in GHRH-dominant scenarios
• Examining functional contribution of GHS-R at low pathway ratios
• Studying GHRH receptor signaling dominance in GH secretion research

Storage and Handling:

• Store at -20°C or -80°C in sealed, inert containers
• Maintain protection from moisture and light exposure
• Reconstitute with sterile peptide buffers maintaining appropriate pH
• Preserve blend homogeneity to avoid component separation

Product Specifications:

• Purity: >97% HPLC combined purity
• Form: Lyophilized powder blend
• Appearance: White to off-white freeze-dried powder
• Quantity: 16 mg total (13 mg tesamorelin + 3 mg Ipamorelin)

FOR RESEARCH USE ONLY. Not intended for human consumption or clinical use. All products are sold strictly for laboratory, educational, and scientific research purposes.